Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

"Most viewed" articles are from the articles published during the last six months

Review

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 4529 Download: 114 Citations: 3

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 3759 Download: 373 Citations: 4

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 2433 Download: 48

Review

Recent updates on the management of autoimmune hepatitis

Atsumasa Komori

Clin Mol Hepatol. 2021;27(1):58-69. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0189

View: 10096 Download: 838 Citations: 30

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0104

View: 3599 Download: 492

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 2719 Download: 454 Citations: 2

Guideline

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clin Mol Hepatol. 2022;28(4):583-705. Published online October 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0294

View: 4147 Download: 385 Citations: 28

Original Article

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients

Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):135-145. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0181

View: 3054 Download: 245 Citations: 4

Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0178

View: 12931 Download: 1,088 Citations: 99

Review

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 6712 Download: 130

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 2845 Download: 173 Citation: 1

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective

Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):230-241. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0421

View: 1845 Download: 222 Citations: 4

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park, Young S. Hahn

Clin Mol Hepatol. 2023;29(1):65-76. Published online August 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0032

View: 2826 Download: 131 Citations: 3

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan

Clin Mol Hepatol. 2023;29(2):277-292. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0212

View: 1782 Download: 267 Citations: 3

Current understanding of primary biliary cholangitis

Atsushi Tanaka

Clin Mol Hepatol. 2021;27(1):1-21. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0028

View: 9112 Download: 642 Citations: 31

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 1875 Download: 143 Citations: 2

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 1842 Download: 242 Citation: 1

Original Article

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi

Clin Mol Hepatol. 2023;29(2):417-432. Published online November 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0205

View: 1723 Download: 97 Citation: 1

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 2426 Download: 179 Citations: 6

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith

Clin Mol Hepatol. 2023;29(2):433-452. Published online January 4, 2023

DOI: https://doi.org/10.3350/cmh.2022.0316

View: 1684 Download: 139 Citations: 4

Review

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 1897 Download: 163 Citations: 5

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 6835 Download: 463 Citations: 20

Review

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 1958 Download: 174 Citations: 2

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 3853 Download: 387 Citations: 23

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 1793 Download: 253 Citations: 2

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 4485 Download: 264 Citations: 7

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective

Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi

Clin Mol Hepatol. 2023;29(2):197-205. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0404

View: 1573 Download: 145 Citations: 3

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 1666 Download: 164 Citations: 3

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 1525 Download: 110 Citations: 2

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 2738 Download: 223 Citations: 2

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Viewed By 4109	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2679	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2433	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Viewed By 2405	Recent updates on the management of autoimmune hepatitis
Viewed By 2402	Management of refractory ascites